PROK PROKIDNEY CORP.

Price Chart

Executive Summary

ProKidney reported Q1 2026 financial results that were in line with consensus, with a net loss of $20.0M available to Class A common stockholders ($-0.14 EPS) versus the $-0.14 estimate. The company reiterated its key clinical milestones: Phase 3 PROACT 1 enrollment completion mid-2026 and pivotal eGFR slope data in Q2 2027. Cash burn accelerated to $41.7M in operating cash flow (vs $29.6M in Q1 2025), reducing the cash runway to $224.9M, still supporting operations into mid-2027. The filing is neutral — no new data, no guidance change, and the clinical timeline remains on track.

Actionable Insight

Key Facts

• Q1 2026 net loss available to Class A common stockholders was $20.0M ($-0.14 EPS), in line with consensus of $-0.14
• Revenue was $226K, essentially flat vs $230K in Q1 2025
• Cash, cash equivalents and marketable securities totaled $224.9M at March 31, 2026, down from $270.0M at December 31, 2025
• Operating cash flow was -$41.7M in Q1 2026 vs -$29.6M in Q1 2025, a 41% increase in cash burn
• Phase 3 PROACT 1 enrollment for accelerated approval efficacy analysis remains on track for mid-2026, with pivotal topline results expected Q2 2027
• The statistical powering assumption for the surrogate endpoint (eGFR slope) was updated to 80% (from prior 90%) in the 8-K Item 8.01
• Cash runway guidance unchanged: operations funded into mid-2027

Financial Impact

Q1 2026 net loss of $20.0M on $226K revenue; cash burn increased 41% YoY to $41.7M operating cash flow; cash position $224.9M provides runway into mid-2027

Risk Factors

• Cash burn accelerated to $41.7M/quarter, reducing runway faster than prior run-rate implied
• Phase 3 PROACT 1 trial failure risk remains binary — no interim data to de-risk
• No new financing announced; if enrollment or data timeline slips, the company may need to raise capital before mid-2027

Market Snapshot

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

US Market Status